[HTML][HTML] Cost-of-illness studies: concepts, scopes, and methods
C Jo - Clinical and molecular hepatology, 2014 - ncbi.nlm.nih.gov
Liver diseases are one of the main causes of death, and their ever-increasing prevalence is
threatening to cause significant damage both to individuals and society as a whole. This …
threatening to cause significant damage both to individuals and society as a whole. This …
[HTML][HTML] Clinical applications of transient elastography
KS Jung, SU Kim - Clinical and molecular hepatology, 2012 - ncbi.nlm.nih.gov
Chronic liver disease represents a major public health problem, accounting for significant
morbidity and mortality worldwide. As prognosis and management depend mainly on the …
morbidity and mortality worldwide. As prognosis and management depend mainly on the …
TUT4/7-mediated uridylation of a coronavirus subgenomic RNAs delays viral replication
Coronaviruses are positive-strand RNA viruses with 3′ polyadenylated genomes and
subgenomic transcripts. The lengths of the viral poly (A) tails change during infection by …
subgenomic transcripts. The lengths of the viral poly (A) tails change during infection by …
Structure–Activity Relationships and Discovery of (S)-6-Isopropyl-2-methoxy-3-(3-methoxypropoxy)-10-oxo-5,10-dihydro-6H-pyrido[1,2-h][1,7]naphthyridine-9 …
D Gotchev, BD Dorsey, D Nguyen… - Journal of Medicinal …, 2024 - ACS Publications
Approved therapies for hepatitis B virus (HBV) treatment include nucleos (t) ides and
interferon alpha (IFN-α) which effectively suppress viral replication, but they rarely lead to …
interferon alpha (IFN-α) which effectively suppress viral replication, but they rarely lead to …
A novel, small anti-HBV compound reduces HBsAg and HBV-DNA by destabilizing HBV-RNA
T Watanabe, S Hayashi, Y Zhaoyu, H Inada… - Journal of …, 2024 - Springer
Background Currently, standard treatments for chronic hepatitis B such as nucleos (t) ide
analogs (NAs), effectively reduce hepatitis B virus (HBV) loads but rarely result in a …
analogs (NAs), effectively reduce hepatitis B virus (HBV) loads but rarely result in a …
[HTML][HTML] Combined effects of synbiotic and sitagliptin versus sitagliptin alone in patients with nonalcoholic fatty liver disease
S Sayari, H Neishaboori… - Clinical and molecular …, 2018 - ncbi.nlm.nih.gov
Methods In total, 138 NAFLD patients aged 18-60 years were enrolled in the study. Patients
were randomized to one of the following treatments for 16 weeks: Group I (n= 68), sitagliptin …
were randomized to one of the following treatments for 16 weeks: Group I (n= 68), sitagliptin …
Discovery, optimization and biological evaluation of novel HBsAg production inhibitors
L Zhang, X Ge, H Jin, D Lu, S Chen, Y Zhang… - European Journal of …, 2023 - Elsevier
Hepatitis B virus (HBV) infection is a major global health problem. HBsAg inhibitors are
expected to reduce the production of HBsAg via inhibiting host proteins PAPD5 & PAPD7 …
expected to reduce the production of HBsAg via inhibiting host proteins PAPD5 & PAPD7 …
Identification of dihydroquinolizinone derivatives with cyclic ether moieties as new anti-HBV agents
X Qin, L Yang, X Ma, B Jiang, S Wu, A Wang… - European Journal of …, 2022 - Elsevier
Abstract RG7834, a dihydroquinolizinone (DHQ) candidate developed by Roche Pharma,
was expected to realize the “functional cure of HBV”. However, it was dismissed in phase I …
was expected to realize the “functional cure of HBV”. However, it was dismissed in phase I …
Identification of dihydroquinolizinone derivatives with nitrogen heterocycle moieties as new anti-HBV agents
H Song, S Yang, S Wu, X Qin, Y Wang, X Ma… - European Journal of …, 2024 - Elsevier
The sustained loss of HBsAg is considered a pivotal indicator for achieving functional cure of
HBV. Dihydroquinolizinone derivatives (DHQs) have demonstrated remarkable inhibitory …
HBV. Dihydroquinolizinone derivatives (DHQs) have demonstrated remarkable inhibitory …
[HTML][HTML] Interferon-free treatment for hepatitis C virus infection induces normalization of extrahepatic type I interferon signaling
Methods A prospective cohort comprising 27 patients under DAA therapy was formed.
Expression level of IFN-β and its downstream interferon-stimulated genes (ISGs) was …
Expression level of IFN-β and its downstream interferon-stimulated genes (ISGs) was …